

**ASX Announcement**

**12 April 2024**

**First patient treated with OncoSil™ device in the UK for the TRIPP-FXX study**

**OncoSil Medical's clinical strategy continues to be progressed, with the first patient treatment using the OncoSil™ device occurring in the UK for the TRIPP-FXX clinical study**

**Key Highlights**

- ✓ The first patient treatment in the UK utilising the OncoSil™ device for the TRIPP-FXX clinical study has taken place.
- ✓ This treatment was undertaken at The Hammersmith Hospital located in London.
- ✓ The TRIPP-FXX study will assess the safety and efficacy of the OncoSil™ device when given with standard FOLFIRINOX chemotherapy for treatment of locally advanced pancreatic cancer.
- ✓ The TRIPP-FXX study has significant scale, covering 16-18 sites in Spain, the UK, Australia, Italy and Belgium.

**Sydney, Australia – 12 April 2024:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“**OncoSil**” or “**the Company**”) is pleased to announce that the first patient treatment utilising the OncoSil™ device for the TRIPP-FXX clinical study has taken place in the UK. This treatment was undertaken at the Hammersmith Hospital, located in London.

**A key milestone in the OncoSil™ device's UK strategy delivered**

The OncoSil™ device has achieved another milestone in its clinical strategy, with the first patient treatment utilising the OncoSil™ device undertaken in the UK for the TRIPP-FXX clinical study on 11 April 2024.

The treatment was delivered at the Hammersmith Hospital, London. This healthcare facility is a specialist hospital renowned for its strong research connections, hosting the clinical sciences centre of the Medical Research Council. Hammersmith Hospital were also a participant in OncoSil's PanCo clinical study.



**Figure 1:** The Hammersmith Hospital in London

### **The significance of the TRIPP-FXX clinical study**

The central objective of the TRIPP-FXX clinical study is to assess the safety and efficacy of the OncoSil™ device when given in addition to standard FOLFIRINOX chemotherapy for treatment of locally advanced pancreatic cancer.

The study has significant scale, covering 16-18 sites in Spain, the UK, , Australia, Italy and Belgium. Currently, 11 sites are open for recruitment, while 29 patients have been recruited to date.

**OncoSil Medical CEO & Managing Director Nigel Lange, said:** *“The first patient treatment using the OncoSil™ device for the TRIPP-FXX clinical study in the UK represents another significant step in our ongoing efforts to expand our label approval to include one of the backbone chemotherapies in combination with our device as a treatment option for patients with locally advanced pancreatic cancer. It provides further proof that OncoSil Medical is successfully executing on two broad-based components of its overall growth strategy. The first of these is to continue our research of the OncoSil™ device through continued clinical studies. The second is to commercialise the device in several key target markets including Western Europe and the UK.”*

## Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

### For further information, please contact:

<p><b>Mr. Nigel Lange</b> CEO &amp; Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 16096424981</p>	<p><b>Mr. Christian Dal Cin</b> CFO &amp; Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254</p>	<p><b>Ms. Julia Maguire</b> <b>The Capital Network</b> Media and Investor Enquiries E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a> T: +61 2 8999 3699</p>
--	--	--

### About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

#### References:

1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>

### About Hammersmith Hospital

Hammersmith Hospital is a specialist hospital renowned for its strong research connections. It offers a range of services, including renal, haematology, cancer and cardiology care, and provides the regional specialist heart attack centre. As well as being a major base for Imperial College, the Acton site also hosts the clinical sciences centre of the Medical Research Council.